Development of an Amplicon-Based Next-Generation Sequencing Assay for Pan-type Detection of BCR::ABL1 Kinase Domain Mutations.
BCR::ABL1 kinase domain (KD) mutations confer tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive (Ph+) leukemia, but conventional Sanger sequencing (SS) has limited sensitivity and most next-generation sequencing (NGS) assays cover only a single transcript type. We developed an amplicon-base...